Immuneering (IMRX) Stock Price, News & Analysis

Company Overview

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $5.58 to $6.35
• 50-Day Range: $3.02 to $5.99
• 52-Week Range: $1.10 to $6.35
• Volume: 879,495 shs
• Average Volume: 859,387 shs
• Market Capitalization: $217.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Moderate Buy

Immuneering Stock Analysis - MarketRank™

Immuneering scored higher than 58% of companies evaluated by MarketBeat, and ranked 312th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Immuneering has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Immuneering are expected to grow in the coming year, from ($1.86) to ($1.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immuneering is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immuneering is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immuneering has a P/B Ratio of 4.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.07% of the float of Immuneering has been sold short.

Short Interest Ratio / Days to Cover

Immuneering has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Immuneering has recently increased by 1.28%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immuneering does not currently pay a dividend.

Dividend Growth

Immuneering does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.07% of the float of Immuneering has been sold short.

Short Interest Ratio / Days to Cover

Immuneering has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Immuneering has recently increased by 1.28%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.36

News Sentiment

Immuneering has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.12 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Immuneering this week, compared to 2 articles on an average week.

Search Interest

Only 5 people have searched for IMRX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Immuneering to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Immuneering insiders have bought more of their company's stock than they have sold. Specifically, they have bought $334,318.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

22.90% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMRX Stock Analysis - Frequently Asked Questions

How have IMRX shares performed this year?

Immuneering's stock was trading at $2.20 at the start of the year. Since then, IMRX stock has increased by 172.3% and is now trading at $5.99.

How were Immuneering's earnings last quarter?

Immuneering Corporation (NASDAQ:IMRX) released its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.40) earnings per share for the quarter, hitting the consensus estimate of ($0.40).

When did Immuneering IPO?

Immuneering (IMRX) raised $105 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

Who are Immuneering's major shareholders?

Top institutional shareholders of Immuneering include Marshall Wace LLP (1.59%), Geode Capital Management LLC (0.64%), Bridgeway Capital Management LLC (0.27%) and Corient Private Wealth LLC (0.18%). Insiders that own company stock include Benjamin J Zeskind, Brett Matthew Hall, Peter Feinberg, Leah R Neufeld, Mallory Morales, Harold Eugene Brakewood and Diana Hausman.
View institutional ownership trends.

How do I buy shares of Immuneering?

Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immuneering own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immuneering investors own include Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/02/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMRX
• CIK: 1790340
• Web: www.immuneering.com
• Phone: 617-500-8080
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Immuneering: $13.00
• High Price Target: $21.00
• Low Price Target: $8.00
• Potential Upside/Downside: +118.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.04 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -146.28%
• Return on Assets: -117.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.70
• Quick Ratio: 3.70

Sales & Book Value

• Annual Sales: $320 thousand
• Price / Sales: 676.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.33 per share
• Price / Book: 4.48

Miscellaneous

• Outstanding Shares: 36,320,000
• Free Float: 28,002,000
• Market Cap: $216.47 million
• Optionable: Not Optionable
• Beta: 0.43